In a secondary analysis of 11,630 ODYSSEY OUTCOMES patients after acute coronary syndrome, doubling OxPL-apoB was associated with MACE in the placebo group (HR 1.081), mainly when Lp(a) was below median; alirocumab lowered OxPL-apoB 13.0% and removed the association.
Secondary analysisn = 11,630
Tsimikas et al. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome